Nicolet Bankshares Inc. boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 13.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,803 shares of the company’s stock after buying an additional 1,047 shares during the period. Nicolet Bankshares Inc.’s holdings in Merck & Co., Inc. were worth $534,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Taylor Wealth Management Partners purchased a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $110,000. Creative Financial Designs Inc. ADV grew its position in shares of Merck & Co., Inc. by 155.2% in the second quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after purchasing an additional 1,114 shares in the last quarter. Clearwater Capital Advisors LLC purchased a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $103,000. SRS Capital Advisors Inc. grew its position in shares of Merck & Co., Inc. by 208.4% in the first quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after purchasing an additional 1,340 shares in the last quarter. Finally, Well Done LLC purchased a new stake in shares of Merck & Co., Inc. in the first quarter valued at approximately $115,000. Institutional investors own 72.20% of the company’s stock.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, June 18th. SunTrust Banks restated a “buy” rating and issued a $77.00 price target on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. TheStreet upgraded Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research report on Friday, June 8th. BMO Capital Markets restated a “buy” rating and issued a $70.00 price target on shares of Merck & Co., Inc. in a research report on Sunday, July 22nd. Finally, Jefferies Financial Group restated a “hold” rating and issued a $59.00 price target on shares of Merck & Co., Inc. in a research report on Sunday, July 15th. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $67.24.

In related news, EVP Adam H. Schechter sold 134,094 shares of the stock in a transaction that occurred on Monday, June 18th. The stock was sold at an average price of $61.00, for a total value of $8,179,734.00. Following the completion of the transaction, the executive vice president now directly owns 100,000 shares in the company, valued at $6,100,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the completion of the transaction, the chairman now owns 938,788 shares of the company’s stock, valued at $61,021,220. The disclosure for this sale can be found here. Insiders sold 396,393 shares of company stock valued at $25,235,061 over the last quarter. 0.32% of the stock is currently owned by company insiders.

Shares of Merck & Co., Inc. stock opened at $68.54 on Friday. The company has a market capitalization of $185.04 billion, a P/E ratio of 16.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.80. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $70.25. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.61.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion during the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 earnings per share. equities research analysts predict that Merck & Co., Inc. will post 4.27 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 5th. Investors of record on Monday, September 17th will be given a $0.48 dividend. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 annualized dividend and a yield of 2.80%. Merck & Co., Inc.’s payout ratio is 48.24%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: Using the New Google Finance Tool

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.